KESTRA MEDICAL TECHNOLOGIES, LTD.

KMTS· Nasdaq· Surgical & Medical Instruments & Apparatus

Market cap
–
P/FCF
–
EV/Sales
–
FCF margin
-122.6%
ROIC, 5 yr avg
–
Revenue, 5 yr CAGR
–
We record prices for the companies we cover; KMTS is not one of them yet.

Company statistics

From the 10-Ks, computed in code · point at a figure for its formula

Profile · FY2026

Market cap
–
Enterprise value
–
Diluted shares
54.2M
Revenue
$95.1M
Free cash flow
-$116.6M
Owner earnings
-$150.2M

Valuation · FY2026

P/E
–
P/FCF
–
P/Owner earnings
–
EV/Sales
–
EV/FCF
–
P/B
–

Margins · FY2026

Gross
51.4%
Operating
-141.6%
Net
-138.4%
Free cash flow
-122.6%
Owner earnings
-157.9%
Stock pay
35.4%

Returns

ROIC, FY2026
–
ROIC, 5 yr avg
–
ROE, FY2026
-50.7%
ROE, 5 yr avg
–

Growth (CAGR)

Revenue, 3 yr
–
Revenue, 5 yr
–
Revenue, 2 yr
84.9%
Diluted EPS, 3 yr
–
Diluted EPS, 5 yr
–
Diluted EPS, 2 yr
–
Free cash flow, 3 yr
–
Free cash flow, 5 yr
–
Free cash flow, 2 yr
–

Financial health · FY2026

Cash and investments
$196.4M
Total debt
$42.6M
Net cash
$153.8M
Debt/Equity
0.2x
Debt/FCF
–

Shareholder returns · FY2026

Dividend yield
–
Payout ratio
–
Buyback yield
–
Shareholder yield
–
Share count, 5 yr
–

Financials: ten years from the 10-Ks

Reported numbers open their filing · computed ones show the formula · ˢ split-adjusted

Revenue

$95.1M

+84.9% a year over 2 years

FY2024: Revenue $27.8MFY2025: Revenue $59.8MFY2026: Revenue $95.1M
FY2024FY2026

Margins

Gross51.4%Operating-141.6%Net-138.4%

FY2026

FY2024: Gross 1.3%, Operating -305.8%, Net -338.4%FY2025: Gross 40.5%, Operating -177.8%, Net -190.3%FY2026: Gross 51.4%, Operating -141.6%, Net -138.4%
FY2024FY2026

Free cash flow and owner earnings

Free cash flow-$116.6MOwner earnings-$150.2M

FY2026

FY2024: Free cash flow -$84.5M, Owner earnings -$85.9MFY2025: Free cash flow -$100.5M, Owner earnings -$124.8MFY2026: Free cash flow -$116.6M, Owner earnings -$150.2M
FY2024FY2026

Diluted shares

54.2M

+172.5% over 2 years, net dilution

FY2024: Diluted shares 19.9MFY2025: Diluted shares 24.6MFY2026: Diluted shares 54.2M
FY2024FY2026

Net cash

$153.8M

$153.8M more cash than debt

FY2024: Net cash -$34.3MFY2025: Net cash $196.5MFY2026: Net cash $153.8M
FY2024FY2026

Every figure, year by year

Fiscal yearFY2024FY2025FY2026
The business
Revenue$27.8M$59.8M$95.1M
Revenue growth–115.1%59.0%
Gross margin1.3%40.5%51.4%
Operating margin-305.8%-177.8%-141.6%
Net income-$94.1M-$113.8M-$131.6M
Net margin-338.4%-190.3%-138.4%
Diluted EPS$-5.07$-5.13$-2.43
Return on invested capital?–––
Cash
Operating cash flow-$72.2M-$77.6M-$81.7M
Capital expenditure$12.2M$22.9M$34.9M
Free cash flow-$84.5M-$100.5M-$116.6M
Stock-based compensation$1.5M$24.3M$33.6M
Owner earnings?-$85.9M-$124.8M-$150.2M
Free cash flow per share$-4.25$-4.09$-2.15
Capital allocation
Dividends paid–––
Share repurchases–––
Diluted shares19.9M24.6M54.2M
Share count change?–23.6%120.4%
Balance sheet
Cash and equivalents$8.2M$237.6M$99.7M
Short-term investments––$96.7M
Total debt$42.5M$41.1M$42.6M
Net debt$34.3M-$196.5M-$153.8M
Shareholders' equity-$209.4M$205.4M$259.7M

Latest filings

All on EDGAR
2026-09-1410-QQuarterly report
2026-09-148-KEarnings release
2026-07-28DEF 14AProxy statement
2026-07-1410-KAnnual report
2026-07-148-KEarnings release
2026-03-1710-QQuarterly report
2026-03-178-KEarnings release
2025-12-1110-QQuarterly report
2025-12-118-KEarnings release
2025-12-018-KEarnings release

More from our coverage

All coverage